Rhonda Farnum - 14 Jul 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: SVP, COMM & MEDICAL AFFAIRS
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol: TBPH
Transactions as of: 14 Jul 2025
Net transactions value: -$113,870
Form type: 4
Filing time: 16 Jul 2025, 18:01:13 UTC
Previous filing: 04 Jun 2025
Next filing: 22 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO	/s/ Brett A. Grimaud, Attorney-in-Fact	16 Jul 2025	0001898490

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBPH	Ordinary Shares	Sale	$7,770	-682	-0.2%	$11.39	336,236	14 Jul 2025	Direct	F1
transaction	TBPH	Ordinary Shares	Sale	$60,548	-5,318	-1.6%	$11.39	330,918	14 Jul 2025	Direct	F2
transaction	TBPH	Ordinary Shares	Sale	$45,552	-4,000	-1.2%	$11.39	326,918	14 Jul 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices from $11.24 to $11.465 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2	This transaction was executed in multiple trades at prices from $11.24 to $11.46 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 03/14/2024.